Related Experiment Videos
Genetic markers in thyroid neoplasia
1Division of Endocrinology and Metabolism, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Endocrinology and Metabolism Clinics of North America
|July 11, 2001
Summary
Genetic testing for cancer, particularly thyroid cancer, aids diagnosis and treatment. While RET oncogene mutations are key for medullary thyroid carcinomas, follicular cell cancer genetics require further research for clinical application.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Cancer is fundamentally a genetic disease.
- Genetic testing is increasingly vital for cancer counseling, diagnosis, and treatment selection.
- Thyroid cancer management has been significantly impacted by genetic insights.
Purpose of the Study:
- To review the role of genetic abnormalities in cancer, with a focus on thyroid cancer.
- To highlight the clinical utility of genetic testing in managing different thyroid cancer subtypes.
- To assess the current and potential future value of genetic research in thyroid cancer.
Main Methods:
- Literature review of genetic alterations in various cancers.
- Specific focus on RET oncogene mutations in medullary thyroid carcinoma.
- Analysis of genetic changes in thyroid follicular cell cancers.
Main Results:
- Genetic testing for RET oncogene mutations has transformed medullary thyroid carcinoma management.
- Significant data exists on genetic alterations in thyroid follicular cell cancers.
- These genetic changes in follicular cell cancers currently lack direct clinical diagnostic or prognostic value.
Conclusions:
- Genetic mutations are central to cancer development and progression.
- Targeted genetic testing, like for RET in medullary thyroid carcinoma, offers clear clinical benefits.
- Further research is needed to translate genetic findings in thyroid follicular cell cancers into practical clinical tools.